Life Science Leader

Transforming Perceptions: Empowering Women to Lead in the Healthcare Industry https://lnkd.in/eYGDxmh3 It seems backwards, but many women fall into a trap in which they are seen as a “doer,” and somehow not considered to be a “leader.” What gives?  - Mary Beth Sandin

TODAY! A Realistic Look at AI/ML Use in Biomanufacturing https://lnkd.in/e5JwN4rH AI and Machine Learning are more than just buzzwords—they're transforming the biopharma industry. But how can we harness their full potential in biomanufacturing? What practical steps can be taken to improve processes, testing, and quality? Join us at 11 a.m. EDT for a Bioprocess Online Live event. Tyler Menichiello hosts a panel with experts: 🎤 Deenadayalan Bakthavatsalam PhD, MBA, CSSBB - CSO, rBIO 🎤 Tinglong Dai, Ph.D. - The Johns Hopkins University - Carey Business School 🎤 Tugce Martagan, Ph.D. - Eindhoven University of Technology Discover practical AI/ML applications, barriers to adoption, and how regulators can drive standardization in biomanufacturing. https://lnkd.in/e5JwN4rH

"One of the areas where we see big opportunity is going to be in the drug discovery space." - Shweta Maniar, Google’s global market leader for life sciences Google Life Sciences Leader Talks AI Opportunities And 'Watch Outs' For Biopharma https://lnkd.in/eZmeQHv4 - By Ben Comer, Chief Editor, Life Science Leader "One of the areas where we see big opportunity is going to be in the drug discovery space." - Shweta Maniar, Google’s global market leader for life sciences

Monday may be Labor Day here in the states, but the #BusinessofBiotech podcast doesn't stop working. This time, Matthew Pillar and I found ourselves marveling over the wonders of circular RNA (and the wonders of the Norwegian landscape in the background) with Circio Holding ASA Erik Digman Wiklund. The full episode drops on Monday, but as you prepare to head off into the long weekend, check out a quick clip from our conversation with Erik here.

GLP-1 Drugs Driving Big Budget Impact: PwC's Medical Cost Trend 2025 https://lnkd.in/eRBdrEuQ "Regarding the GLP-1 class of drugs, the name of the game is utilization, or increased patient access via improved insurance coverage", says Philip Sclafani, a partner in PwC’s pharmaceutical and life sciences practice.

'Doers, not Leaders': How Women Can Overcome A Common Workplace Struggle https://lnkd.in/ew5hFgAj - By Mary Beth Sandin Today, only 15 percent of CEOs in the healthcare industry are women, and of the 10 leading pharmaceutical companies globally, only 22 percent of their executive teams are women.

GLP-1 Drugs Driving Big Budget Impact: PwC's Medical Cost Trend 2025 https://lnkd.in/e6czNeMR The medical cost trend increased each year by a more or less consistent rate of between 5% and 6%. In 2025, however, PwC anticipates an 8% increase.

Mid-Year M&A Outlook: Challenges And Opportunities Update https://lnkd.in/eQ8wvhc4 Current market conditions suggest that valuations will remain subdued until there's more certainty about long-term inflation and interest rates. 

Payer revenue optimization tactics are widening the gross-to-net bubble for pharma companies. https://ow.ly/R0Vm50SEHJv In Life Science Leader, MMIT's Dinesh Kabaleeswaran and Jen Klarer, partner at The Dedham Group, discuss how pharma is shifting to early-stage market access planning in response. Click the link to check out the insights!

This Takeda Official Thinks Pharma 4.0 Won't Be Optional Much Longer https://lnkd.in/ebtAnKwE A conversation with Gunter Baumgartner, Takeda